Roche adds Galaxy FGF2 MAbs to complement internal project

Roche has licensed exclusive worldwide development and commercialisation rights to Galaxy Biotech's antibodies targeting fibroblast growth factor 2 (FGF2) for the treatment of cancer.

Roche has licensed exclusive worldwide development and commercialisation rights to Galaxy Biotech's antibodies targeting fibroblast growth factor 2 (FGF2) for the treatment of cancer.

Roche's Dr Klaus Bosslet, head of discovery oncology, told Scrip that the FGF2 programme "complements its in-house portfolio" and will...

More from Anticancer

Roche’s evERA Giredestrant Study Hits In All-Comer Breast Cancer Population

 

The Phase III trial of the SERD has shown a significant benefit in the intent-to-treat and ESR1-mutated populations in post-CDK ER+/HER2- metastatic breast cancer but whether the data will be enough to support an equally broad approval remains to be seen.

Merck Scores US FDA Approval For Subcutaneous Keytruda Qlex

 

The agency approved the subcutaneous formulation of the PD-1 inhibitor, months after approving a subcutaneous version of BMS’s Opdivo.

Regeneron To Pit Lynozyfic Against J&J’s Darzalex In Smoldering Myeloma

 

The drugmaker presented positive Phase II data for its BCMAxCD3-directed bispecific in high-risk smoldering myeloma patients.

Nanobiotix/J&J Early Melanoma Data Show Potential For Future Indication

 
• By 

Radiotherapy enhancer JNJ-1900 (NBTXR3) generated a 47% ORR and 78.9% DCR in melanoma patients after multiple prior rounds of treatment. Discussions about development in additional cancers are ongoing with partner J&J.

More from Therapeutic Category

Roche’s evERA Giredestrant Study Hits In All-Comer Breast Cancer Population

 

The Phase III trial of the SERD has shown a significant benefit in the intent-to-treat and ESR1-mutated populations in post-CDK ER+/HER2- metastatic breast cancer but whether the data will be enough to support an equally broad approval remains to be seen.

Sanofi’s Pipeline Pressure Continues As Tolebrutinib Trips Near Finish Line

 
• By 

Sanofi’s MS hopeful tolebrutinib hits a regulatory hurdle in the US, renewing pressure on the firm’s pipeline. Analysts hope the delay won’t prove material.

Why India Revoked The Entresto Patent And Novartis Abstained From Proceedings

 

India revokes Novartis's patent pertaining to Entresto, upholding the objections of opponents including the Indian Pharmaceutical Alliance on lack of novelty and prior claiming, among others. Novartis decided against participating in the hearings.